Bristol-Myers Beats Second-Quarter Estimates

Bristol-Myers Beats Second-Quarter Estimates

Bristol Myers trumps analysts’ estimates on strong sales of its cancer immunotherapy and cardiology drugs

Bristol-Myers Beats Second-Quarter Estimates

comments powered by Disqus